Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy

Zhou,Jixiang; Li,Xiaoli

doi:10.3892/ol.2018.9458

Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy

Authors:
- Jixiang Zhou
- Xiaoli Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: September 19, 2018 https://doi.org/10.3892/ol.2018.9458
Pages: 6633-6637
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the effects of phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression on liver function classification, serum tumor markers and liver function of patients with liver cancer. A total of 63 patients with primary liver cancer treated in Xiangya Hospital (Changsha, China) were retrospectively analyzed. The difference in the PTEN expression levels in normal liver cells and liver cancer cells was compared via immunohistochemistry. According to the expression level of PTEN in the patient's pathological report, patients were divided into PTEN‑positive and PTEN‑negative groups. The expression level of each tumor marker in serum of patients was observed, and the association of PTEN expression level with the serum tumor markers was analyzed. Moreover, the changes in liver function and inflammatory factors before and after chemotherapy were compared. Finally, the relationship between the PTEN expression level and Child‑Pugh grading of the liver function was detected. Compared with that in normal liver cells, the positive expression rate of PTEN protein in liver cancer cells was significantly decreased (P<0.05). No significant difference was found in the expression levels of serum tumor markers, except α‑fetoprotein (AFP) in liver cancer patients between PTEN‑positive and PTEN‑negative group, indicating that PTEN expression has no significant effects on serum tumor markers. The levels of albumin (ALB), alkaline phosphatase (ALP) and prothrombin activity (PTA) were decreased significantly after chemotherapy compared with those before chemotherapy (P<0.05). Besides, the levels of inflammatory factors were remarkably reduced after chemotherapy. PTEN expression was negatively associated with liver function grading, and the higher the PTEN expression, the lower the liver function grading was. The low expression of PTEN has a certain association with the occurrence and grading of liver cancer. PTEN gene has guiding significance in predicting the occurrence, development and prognosis of liver cancer.

View Figures

View References

1	Gravitz L: Liver cancer. Nature. 516:S12014. View Article : Google Scholar : PubMed/NCBI
2	Shibata T, Chuma M, Kokubu A, Sakamoto M and Hirohashi S: EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
3	Alioui A, Dufour J, Leoni V, Loregger A, Moeton M, Iuliano L, Zerbinati C, Septier A, Val P, Fouache A, et al: Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer. Nat Commun. 8:4452017. View Article : Google Scholar : PubMed/NCBI
4	Seo JH, Ahn Y, Lee SR, Yeo Yeol C and Hur Chung K: The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol Biol Cell. 16:348–357. 2005. View Article : Google Scholar : PubMed/NCBI
5	Furnari FB, Lin H, Huang HS and Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 94:12479–12484. 1997. View Article : Google Scholar : PubMed/NCBI
6	Dahia PL: PTEN, a unique tumor suppressor gene. Endocr Relat Cancer. 7:115–129. 2000. View Article : Google Scholar : PubMed/NCBI
7	Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
8	Shearn CT and Petersen DR: Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma. Adv Exp Med Biol. 815:173–184. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lu DD, Zhang XR and Cao XR: Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med. 7:67–71. 2003. View Article : Google Scholar : PubMed/NCBI
10	Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
11	Weng L, Brown J and Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet. 10:237–242. 2001. View Article : Google Scholar : PubMed/NCBI
12	Tamura M, Gu J, Takino T and Yamada KM: Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 59:442–449. 1999.PubMed/NCBI
13	Zhang L, Yu Q, He J and Zha X: Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem. 262:25–33. 2004. View Article : Google Scholar : PubMed/NCBI
14	Weng LP, Smith WM, Brown JL and Eng C: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet. 10:605–616. 2001. View Article : Google Scholar : PubMed/NCBI
15	Yuan XJ and Whang YE: PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 21:319–327. 2002. View Article : Google Scholar : PubMed/NCBI
16	Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuchiya M and Nagasue N: Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: Possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 100:152–157. 2002. View Article : Google Scholar : PubMed/NCBI
17	Wan XW, Jiang M, Cao HF, He YQ, Liu SQ, Qiu XH, Wu MC and Wang HY: The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol. 129:100–106. 2003.PubMed/NCBI
18	Ginn-Pease ME and Eng C: Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G₀-G₁ in MCF-7 cells. Cancer Res. 63:282–286. 2003.PubMed/NCBI
19	Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, Perng LI, Wang JC, Tsai M and Chang CP: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. Cancer Invest. 18:123–129. 2000. View Article : Google Scholar : PubMed/NCBI
20	Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, et al: PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene. 18:3181–3185. 1999. View Article : Google Scholar : PubMed/NCBI